In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...

Here’s my take on myeloma-related studies that I’m excited about now and in the year ahead, with a focus on smoldering multiple myeloma ... improve asymptomatic laboratory and imaging findings ...

NAYA Biosciences, Inc. ("NAYA") (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients ...

Welcome to the Adaptive Biotechnologies Fourth Quarter and Full Year 2024 Financial Results Conference Call ... support accelerated approval of multi myeloma therapies, represents a paradigm ...

Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test and an ODAC vote supporting MRD as a primary endpoint for multiple myeloma therapies. The company delivered a record ...

is pleased to announce that it has presented the most recent performance results of its TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients at the recent International ...

Kyle Piskel; Chief Financial Officer; Adaptive Biotechnologies Corp Susan Bobulsky; Chief Commercial Officer, MRD; Adaptive Biotechnologies Corp Harlan Robins; Co-Founder, Chief Scientific Officer; ...

Although the reference ranges of values—meaning the range between which test results are normal—can differ by the lab, an A/G ratio between 1. ... Plasma cell neoplasms (including multiple myeloma) ...

Results: We identified 70 differentially expressed NETs ... cell apoptosis and autophagy and has been applied in the treatment of refractory/relapsed multiple myeloma (Richardson et al., 2010). In ...

However, some studies revealed that high exposure to “agent orange” was associated with a significantly higher prevalence of cancers (colon cancer, leukemia, and multiple myeloma), circulatory ...

Results: The temporal distribution of first-ever stroke in ... and stroke only (Figure 1). Figure 1. Flow chart of enrollment. NHIRD, National Health Insurance Research Database; ICD9-CM, the Ninth ...